Skip to Content
Merck
All Photos(1)

Documents

Safety Information

42000601

Sigma-Aldrich

PRONOVA® UP VLVM

very low viscosity sodium alginate, viscosity <20 mPa.s, 1 %(20 °C)(low), mannuronate monomer units ≥50 %

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

UNSPSC Code:
12162002
NACRES:
NA.25

Quality Level

100

form

powder

mol wt

Mw <75 kDa (approximate)

composition

mannuronate monomer units, ≥50%
G/M ratio, ≥1.5

impurities

≤100 CFU/g Total viable count
≤100 EU/g Endotoxins

pH

5.5-8.5 (20 °C, 1% in water)

viscosity

<20 mPa.s, 1 %(20 °C) (
low)

General description

PRONOVA UP VLVM is a very low viscosity (less than 20 mPas) sodium alginate where minimum 50% of the monomer units are mannuronate.

Application

Examples of Pronova Alginates applications include: encapsulation of living cells and therapeutic proteins for cell therapy medications, cryoprotectant, bone putty binder for tissue engineering, 3D bioprinting, foams and cell tissue scaffolds, hydrogels, advanced drug delivery and implants, wound management, and medical devices.

Legal Information

Product of Dupont Nutrition USA, Inc.
PRONOVA is a registered trademark of International N&H USA, Inc.

Disclaimer

NOT FOR USE IN HUMANS

Storage Class Code

11 - Combustible Solids

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

JAN Code

42000601-10G:
42000601-5G:

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Articles

Rational Design of ECMs Toward Cancer Immunotherapy

Engineered ECMs enhance immune therapy in cancer treatment by supporting cells and tissues and modulating immune response. They improve immune cell maturation, expansion, and regulation through biomaterial manipulation, acting as frameworks or carriers for enhanced tumor immunotherapy.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service